Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPinheiro, Iris
dc.contributor.authorBarbera Belles, Aurora
dc.contributor.authorRaurell Saborit, Immaculada
dc.contributor.authorEstrella Gonzalez, Federico
dc.contributor.authorde Leeuw, Marcel
dc.contributor.authorBolca, Selin
dc.contributor.authorSalcedo Allende, Maria Teresa
dc.contributor.authorGenescà Ferrer, Joan
dc.contributor.authorMartell Pérez-Alcalde, María
dc.contributor.authorAugustin Recio, Salvador
dc.date.accessioned2022-09-09T08:29:39Z
dc.date.available2022-09-09T08:29:39Z
dc.date.issued2022-05-20
dc.identifier.citationPinheiro I, Barberá A, Raurell I, Estrella F, de Leeuw M, Bolca S, et al. A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. Biomedicines. 2022 May 20;10(5):1191.
dc.identifier.issn2227-9059
dc.identifier.urihttp://hdl.handle.net/11351/8097
dc.descriptionBacterial consortium; Gut microbiome; Portal hypertension
dc.description.abstractThe gut microbiome has a recognized role in Non-alcoholic fatty liver disease (NAFLD) and associated comorbidities such as Type-2 diabetes and obesity. Stool transplantation has been shown to improve disease by restoring endothelial function and insulin signaling. However, more patient-friendly treatments are required. The present study aimed to test the effect of a defined bacterial consortium of nine gut commensal strains in two in vivo rodent models of Non-alcoholic steatohepatitis (NASH): a rat model of NASH and portal hypertension (PHT), and the Stelic animal (mouse) model (STAM™). In both studies the consortium was administered orally q.d. after disease induction. In the NASH rats, the consortium was administered for 2 weeks and compared to stool transplant. In the STAM™ study administration was performed for 4 weeks, and the effects compared to vehicle or Telmisartan at the stage of NASH/early fibrosis. A second group of animals was followed for another 3 weeks to assess later-stage fibrosis. In the NASH rats, an improvement in PHT and endothelial function was observed. Gut microbial compositional changes also revealed that the consortium achieved a more defined and richer replacement of the gut microbiome than stool transplantation. Moreover, liver transcriptomics suggested a beneficial modulation of pro-fibrogenic pathways. An improvement in liver fibrosis was then confirmed in the STAM™ study. In this study, the bacterial consortium improved the NAFLD activity score, consistent with a decrease in steatosis and ballooning. Serum cytokeratin-18 levels were also reduced. Therefore, administration of a specific bacterial consortium of defined composition can ameliorate NASH, PHT, and fibrosis, and delay disease progression.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesBiomedicines;10(5)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectHipertensió portal
dc.subjectEsteatosi hepàtica - Prognosi
dc.subjectIntestins - Microbiologia
dc.subject.meshNon-alcoholic Fatty Liver Disease
dc.subject.meshMicrobial Consortia
dc.subject.meshHypertension, Portal
dc.titleA Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/biomedicines10051191
dc.subject.decsesteatosis hepática no alcohólica
dc.subject.decsconsorcios microbianos
dc.subject.decshipertensión portal
dc.relation.publishversionhttps://doi.org/10.3390/biomedicines10051191
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Pinheiro I, de Leeuw M, Bolca S] MRM Health NV, Ghent, Belgium. [Barberá A, Estrella F] Unitat Hepàtica, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Raurell I, Genescà J, Martell M, Augustin S] Unitat Hepàtica, Servei de Medicina Interna, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Centro De Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto De Salud Carlos III, Madrid, Spain. [Salcedo MT] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35625927
dc.identifier.wos000801867000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record